Witryna23 wrz 2024 · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe … WitrynaThis is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 450 participants. Participants will be randomized to receive ISIS …
NCT03385239 DrugSheet
Witryna1 gru 2024 · Overview. This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in participants with hypertriglyceridemia … WitrynaThis is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen … medication glass vials
A Study of ISIS 678354 Administered to Participants With Severe ...
WitrynaWe have now released the latest update to our report on the clinical trials landscape in Australia (2006 – 2024), which outlines key characteristics of clinical trials over time.. Registering a new trial? Videos on how to complete Step 3: Intervention, Step 4: Outcomes and Step 11: Data sharing are available.. To achieve prospective … Witryna29 wrz 2024 · ISIS 678354-CS3 2024-002536-67 ( EudraCT Number ) First Posted: September 29, 2024 Key Record Dates: Last Update Posted: August 9, 2024 Last … WitrynaSponsor Protocol Number: ISIS678354-CS5: Start Date *: 2024-07-22: Sponsor Name: Ionis Pharmaceuticals, Inc. Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia: Medical condition: Severe hypertryglyceridemia: Disease: … nabh entry level accredited hospital